October 1, 2005 |
Andrew von Eschenbach, named last week as interim Food and Drug Administration commissioner to replace Lester Crawford, will take a leave of absence from his job as director of the National Cancer Institute, Sen. Barbara Mikulski said. Von Eschenbach also will "refrain from selected FDA activities that may be seen as a conflict of interest," Mikulski, a Maryland Democrat, said in a statement.
December 5, 1985 |
News of a promising new cancer treatment at the National Cancer Institute prompted a flood of calls to the federal center today from people desperate for a cure from the disease. The callers want information about a new treatment, called adoptive immunotherapy, that turns ordinary white blood cells into "killer cells" that attack malignant tumors. The treatment was announced Wednesday in an article in the New England Journal of Medicine. (Story, Page 12)
March 18, 1989 |
Former U.S. Rep. Bill Chappell Jr. (D-Fla.), defeated last year after 20 years in Congress, said Friday that he is being treated for bone cancer. Chappell, 67, was admitted to the Warren Grant Magnuson Clinical Center in Bethesda, Md., on Feb. 23 by the National Cancer Institute and is in stable condition, a spokeswoman said.
November 5, 1994 |
Test-tube experiments at a National Institutes of Health laboratory show evidence that a drug called hydroxyurea may block or slow the replication of the AIDS virus, researchers report. In a study published in the journal Science, researchers at the National Cancer Institute report that HIV, which causes AIDS, is unable to reproduce in cells exposed to hydroxyurea, a cancer drug that has been used for 30 years.
February 27, 1993 |
Guidelines for breast cancer screening could be changed by some medical organizations once they fully analyze new studies showing mammograms may provide little benefit for women before age 50, officials said. Dr. Gerald P. Murphy, chief medical officer at the American Cancer Society, said his group is examining the new studies, but "not all of the information has been evaluated, and there are no conclusions that can be made on this as yet."
May 8, 1987
A controversial drug to treat two lethal types of cancer has won approval from the Food and Drug Administration for wider trials in humans, it was announced. An FDA spokeswoman said the agency will permit the National Cancer Institute to expand the use of interleukin-2 to a larger number of patients with advanced melanoma and kidney cancer. The treatment will be available to patients selected for participation in tests at NCI-approved cancer centers.